Novavax vs Valneva
NVAX and VALN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NVAX and VALN compare
Valneva grew revenue faster over the last twelve months (−27.2% versus −61.3% for Novavax).
Novavax scores higher on the StockData Score (5 against 1 for Valneva), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NVAX | VALN |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | – |
| Share price | $8.53 | $5.66 |
| Change, 1 year | 18.4% | −38.4% |
| Change, 5 years | −95.6% | −88.4% |
| Beta (5Y) | 1.92 | 1.67 |
| Employees | 749 | 140 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.4× | – |
| Growth | ||
| Revenue growth (TTM) | −61.3% | −27.2% (better) |
| Revenue growth, 5Y average | 18.8% (better) | 9.6% |
| Net income growth (TTM) | −122% | – |
| EPS growth (TTM) | −127% | – |
| Profitability | ||
| Gross margin | 78.0% (better) | 16.4% |
| Operating margin | −21.2% (better) | −80.5% |
| Net margin | −18.6% | – |
| FCF margin | – | −40.6% |
| Financial health | ||
| Interest coverage | −4.0× | −2.8× (better) |
| Current ratio | 2.15 | 2.16 (better) |
| Altman Z-score | −5.94 | – |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 71.2% | 2.2% |
| Held by insiders | 9.2% | 11.0% |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 30.9% | – |
Go deeper
- NVAX stock overview
- NVAX income statement
- NVAX valuation and score
- VALN stock overview
- VALN income statement
- VALN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.